For instance, in PDAC, cervical cancer and multiple myeloma (MM), hnRNPA2/B1 could promote cancer cell growth and metastasis and impair their sensitivity to gemcitabine, 5-fluorouracil (5-FU), oxaliplatin, lobaplatin and irinotecan by activating KRAS-PI3K interaction or regulating ILF3-mediated Akt signals [83–86]. This evidence concerns the gene HNRNPA2B1 and cancer.